Search PubMed⌕ Search

Biomedical subjects

C Cornu

Publications and source records attributed to C Cornu.

At least 73 records · Page 4Linked to original sources
PubMed1990

Prospective trial of recombinant leucocyte interferon in chronic hepatitis B: a long-term follow-up study.

Twenty-one adult patients with chronic hepatitis B and active viral replication as indicated by positivity for hepatitis B e antigen and hepatitis B virus DNA, with increased DNA polymerase levels for more than 6 months, were entered into a prospective trial of low-dose recombinant human alpha-interferon therapy. All patients were treated with 5 million units of recombinant interferon alfa-2b given subcutaneously every other day for 12 weeks. During treatment, 18 patients (86%) showed a significant reduction of DNA polymerase levels (p less than or equal to 0.001), which reached normal values in ten (48%). After 10 months' mean follow up, seven patients (33%) were hepatitis B e antigen negative and five (24%) subsequently became positive for antibodies to e antigen. By 27 months, nine patients (43%) were both hepatitis B e antigen negative and e antibody positive. Only one patient became permanently negative for hepatitis B surface antigen. One patient relapsed during the second year of follow up. Side effects necessitated withdrawal of therapy in two patients: one due to worsening thrombocytopenia after two doses of interferon (data omitted from the study results) and one due to a local reaction at the injection sites. Our data indicate that small doses of recombinant interferon alfa-2b given during a 12-week period induce a significant reduction in viral replication and approximately triple the spontaneous seroconversion rate observed in patients with chronic hepatitis B.

Alanine Transaminase↗
PubMed1989

Prospective trial of recombinant leucocyte interferon in chronic hepatitis B: a 10-month follow-up study.

Twenty-one adult patients with chronic hepatitis B and active viral replication as indicated by the presence of hepatitis Be antigen (HBeAg), increased DNA polymerase (DNAp) and positive hepatitis B virus DNA (HBV-DNA) for more than 6 months, were entered into a prospective trial of recombinant human interferon therapy. Ten patients had chronic persistent or chronic lobular hepatitis, 8 chronic active hepatitis and 3 postnecrotic cirrhosis. All cases were treated with 5 x 10(6) units of recombinant interferon alfa-2B given subcutaneously every other day for 12 weeks. During treatment, 18 patients (86%) showed a significant reduction of DNAp levels, which reached normal values in 10 patients (48%). Viral replication was controlled over a 10-month follow-up period in 7 out of 21 patients (33%). Of these 7, five patients became HBeAg negative and HBeAb positive. HBsAg disappeared in one patient. The only serious adverse effect was thrombocytopenia in one patient in whom rapid recovery occurred when interferon was withdrawn. Treatment was also terminated in a second patient because of local reactions at the injection sites occurring after 10 weeks of therapy. Our data indicate that relatively small doses of recombinant alfa-2B interferon given during a 12-week period induce a significant reduction in viral replication and might approximately triple the spontaneous seroconversion rate observed in patients with chronic hepatitis B.

Adult↗
PubMed1982

Epstein-barr virus VCA IgM and EBNA IgG antibodies titered by immunofluorescence in microplates. A semi-automated method based on microtiter system.

We describe methods of immunofluorescence in microplates for titration of EBV VCA-IgM and EBNA-IgG antibodies and compare the sensitivity of the methods with glass slides and with microplates, showing the reproducibility of the methods. Results of VCA-IgM and -IgG, EA and EBNA titers obtained in four groups of patients are given, comprising cases of infectious mononucleosis, renal graft recipients, lymphoproliferative diseases and controls.

Acute Disease↗
PubMed1979

Poliovirus antibodies in age groups: an assessment of obligatory vaccination in Belgium.

Since 1967, compulsory oral vaccination before 2 years of age has been nearly the only form of poliovaccination practiced in Belgium, and there have been almost no cases of polio. In recent sera from 2,225 Belgians, 2 year olds lacked demonstrable seroneutralizing antibody, in 31% for type 1, in 8% for type 2, and in 21% for type 3. The lack of antibodies grew as the children reached 11--12 years, at which age 65% lacked antibody for type 1, 15% for type 2, and 54% for type 3; only 19% had antibodies against all types. It is argued that this decline of antibodies is not due to insufficient vaccination in former years, but is a strong example of the waning of vaccine-acquired serum antibody. Antibody rates went up after age 12. The highest rates of types 1 and 3 antibodies were seen at age 20--59. There was some decrease of antibody after 60 years. Mean antibody titers paralleled positivity rates. Results of two laboratories studying different populations with different standard techniques were similar. The data support revaccination at school entrance.

Adolescent↗
PubMed1978

Transfer of antibodies against the CPD virus through colostrum and milk.

Newborn lamb immunoglobulins are of maternal origin and the transfer is done exclusively by colostrum and milk (syndesmochorial placentation). Antibody levels in colostrum and in maternal serum are the same at the moment of lambing. Milk antibodies are synthesized by cells which invade the udder at the end of the milking period. We immunized ewes with C.P.D. virus during gestation or at the end of lactation and we evaluated the presence of specific neutralizing antibodies in colostrum, in milk and in the sera of the mother and lamb. We recommend vaccination during pregnancy for ewes which are not going to feed their lambs: colostral given protection persists for 3 or 4 weeks. Ewe vaccination when the udder dried up is the choice when natural suckling is used: the lamb is protected as long as it is with its mother. In the conditions used in this work the steroid injection did not interfere with colostral antibody transmission.

Animals↗